The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue 11, Pages 1783-1786
Publisher
Springer Nature
Online
2017-05-24
DOI
10.1007/s00259-017-3707-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
- (2017) Frederik A. Verburg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
- (2017) Anna Sundlöv et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
- (2016) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison
- (2016) S. Gnesin et al. JOURNAL OF NUCLEAR MEDICINE
- The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres
- (2016) Carlo Chiesa Physica Medica-European Journal of Medical Physics
- A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres
- (2015) Kathy P. Willowson et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology
- (2015) C. Chiesa et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE Therapy
- (2015) P. Kletting et al. JOURNAL OF NUCLEAR MEDICINE
- 99mTc-MAA-Based Dosimetry for Liver Cancer Treated Using 90Y-Loaded Microspheres: Known Proof of Effectiveness
- (2014) E. Garin et al. JOURNAL OF NUCLEAR MEDICINE
- Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective
- (2014) Marta Cremonesi et al. Frontiers in Oncology
- Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies
- (2012) Verena Hartung-Knemeyer et al. ANNALS OF NUCLEAR MEDICINE
- Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study
- (2012) Vincenzo Mazzaferro et al. HEPATOLOGY
- Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study
- (2012) Maarten LJ Smits et al. LANCET ONCOLOGY
- Efficacy of DosimetricVersusEmpiric Prescribed Activity of131I for Therapy of Differentiated Thyroid Cancer
- (2011) Joanna Klubo-Gwiezdzinska et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience
- (2009) Frederik A. Verburg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma
- (2008) Jong Jin Lee et al. ANNALS OF NUCLEAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started